Navigation Links
Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012
Date:8/7/2012

MONMOUTH JUNCTION, N.J., Aug. 7, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today reported results for the second quarter and six-months ended June 30, 2012.

Key Recent Highlights:

  • Dosed first patient in April in CLEAR-108 phase 3 European and Canadian registration study of ARIKACE® in patients with cystic fibrosis who have Pseudomonas aeruginosa lung infections; approximately 65 of 80 planned sites activated and recruiting patients
  • Dosed first patient in June in the U.S. TARGET-NTM phase 2 trial of ARIKACE in patients with non-tuberculous mycobacteria (NTM) lung infections
  • Secured $20 million term loan from Hercules Technology Growth Capital, Inc.
  • Granted second composition of matter patent for ARIKACE by U.S. Patent and Trademark Office
  • "We have successfully transitioned Insmed into a phase 3 development stage company, a significant milestone in our history," said Timothy Whitten, President and CEO of Insmed.  "During the second quarter, Insmed made substantial progress in advancing ARIKACE in the clinic in our two priority orphan indications.  We continue to expect top-line data from CLEAR-108 in mid-2013 and top-line results from the randomized part of TARGET-NTM in the fourth quarter of 2013.  In addition, we recently secured a term loan from Hercules for up to $20 million, $10 million of which has been funded, that will extend our cash runway well into 2014 and provide the Company with further financial stability and flexibility."

    Financial Results:For the second quarter of 2012, Insmed posted a net loss attributable to common stockholders of $9.7 million, or $0.39 per common share – basic and diluted, as compared to a net loss of $10.0 million or $0.40 per common share – basic and diluted, for the
    '/>"/>

    SOURCE Insmed Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
    2. Insmed Incorporated Provides Corporate Update
    3. Organogenesis Announces Annual College Scholarship Award Winner
    4. Bion Announces Approval of New Canadian Patent
    5. PDL BioPharma Announces Second Quarter 2012 Financial Results
    6. BioPower Operations Corporation Announces that FTZ Exchange Signs Strategic Alliance with Capacity 360, LLC and Tom Settineri
    7. Accuray Announces First CyberKnife System in South America
    8. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
    9. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
    10. AMRI Announces Second Quarter 2012 Results
    11. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... synthetic processes prefer to settle into equilibriuma state ... within the realm of non-equilibrium conditions where new ... energy and phases, such as temperature fluctuations, freezing ... to regulate their body temperature, airplanes to fly, ... , But even though these conditions exist ...
    (Date:7/24/2014)... July 24, 2014 Your cell ... in modeling lithium-ion battery storage capacity. , New ... a theoretical model created at Lawrence Livermore ... that predicts how carbon components will perform as ... emphasizes the urgent need for higher-performance batteries. Several ...
    (Date:7/24/2014)... 24, 2014 Three companies from the ... Livestrong’s Big C Competition. Out of 700 competition entrants, ... to the semi-final round. In this round twenty teams ... program, complete with mentoring from thought-leaders and medical entrepreneurs ... of the angelMD commitment to the Livestrong vision around ...
    (Date:7/24/2014)... 2014 WIRB-Copernicus Group ® ("WCG")™, ... review services for clinical research, announced today that ... of Richmond, VA -based Alliance ... biosecurity consulting firm in the United ... division – WCG Biosafety™ – will be able ...
    Breaking Biology Technology:New approach to form non-equilibrium structures 2Getting More Life out of Lithium-ion Batteries 23 angelMD Startups Make Livestrong Big C Semi-finals 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3
    ... valuable source of biofuel. Researchers writing in BioMed Central,s ... shown that the juice of reject watermelons can be ... a team of researchers at the USDA-Agricultural Research Service,s ... to evaluate the biofuel potential of juice from ,cull, ...
    ... , , NEW YORK, ... filed suit yesterday against Celgene Corporation (Nasdaq: CELG ... "unjust enrichment" regarding the Company,s sale of thalidomide (THALOMID(R) and ... alleges that Ms. Jacobson developed the original and novel idea ...
    ... , , SAN ... ), a biopharmaceutical company focused on developing and commercializing novel pain ... its Board of Directors as a director and Audit Committee chairman, ... CEO of Keren Pharmaceutical, a company focused on exploiting a novel, ...
    Cached Biology Technology:NeurogesX Appoints New Board Director and Audit Committee Chairman 2NeurogesX Appoints New Board Director and Audit Committee Chairman 3NeurogesX Appoints New Board Director and Audit Committee Chairman 4NeurogesX Appoints New Board Director and Audit Committee Chairman 5
    (Date:7/24/2014)... wildlife loss leads to conflict among people around the ... Society (WCS) Health & Ecosystems: Analysis of Linkages (HEAL) ... approach to tackle global biodiversity decline. , The harvest ... world,s people and provides protein for more than a ... no surprise that today,s unprecedented loss of wildlife, is ...
    (Date:7/24/2014)... 2014) Scientists at The New York Stem ... closer to creating a viable cell replacement therapy ... , For the first time, NYSCF scientists ... skin samples of patients with primary progressive multiple ... to induce these stem cells into becoming oligodendrocytes, ...
    (Date:7/24/2014)... effects on different species of fish, according to ... and Exeter which tested fish anti-predator behaviour. ... seagull predator model when exposed to additional noise, ... , Lead author Dr Irene Voellmy of ... in many aquatic environments have increased substantially during ...
    Breaking Biology News(10 mins):New study draws links between wildlife loss and social conflicts 2NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
    ... In the May 15th issue of G&D, Dr. Michael Carey ... into the mechanism of epigenetic silencing of euchromatic genes. ... direction to understand how histone and DNA methylation, two phenomena ... cancer, can communicate with each other to turn genes off. ...
    ... a mystery why the speed and complexity of evolution appear ... that single-celled life first appeared about 3.5 billion years ago, ... multi-cellular life to evolve. That leaves just a billion years ... plants, mammals, insects, birds and other species that populate the ...
    ... have developed an inexpensive, nonchlorine-based technology that can ... , UD's patented technology, developed jointly by ... Resources and the College of Engineering, incorporates highly ... a chemical "knock-out punch" to a host of ...
    Cached Biology News:Does evolution select for faster evolvers? 2New UD technology removes viruses from drinking water 2New UD technology removes viruses from drinking water 3New UD technology removes viruses from drinking water 4
    ...
    Mouse monoclonal [Ley 37D/G6] to LKB1 ( Abpromise for all tested applications). entrezGeneID: 6794 SwissProtID: Q15831...
    ... phase reagent for Virus ... & unique water insoluble ... detergents and chaotropes; Engineered ... non-envelop viruses while preserving ...
    Integrins Sampler Kit 10g each...
    Biology Products: